Terms & Conditions

1. Acceptance of Terms

By accessing or using this website (www.tcelltech.com), you agree to be bound by these Terms & Conditions. If you do not agree with any part of these terms, please do not use our website.

2. Use of the Website

You agree to use this website only for lawful purposes and in a way that does not infringe the rights or restrict the use of this site by any third party. Prohibited behavior includes but is not limited to:

3. Intellectual Property

All content on this website—including text, graphics, logos, images, and software—is the property of Tcelltech or its licensors and is protected by intellectual property laws. You may not copy, reproduce, modify, or distribute any content without prior written consent.

4. Limitation of Liability

Tcelltech provides this website “as is” without any warranties, express or implied. We are not liable for:

5. Third-Party Links

Our website may contain links to third-party websites. We are not responsible for the content or privacy practices of these external sites.

6. Changes to the Terms

We reserve the right to update or modify these Terms & Conditions at any time without prior notice. Continued use of the website after changes implies acceptance of the updated terms.

7. Contact

If you have any questions about these Terms & Conditions, please contact us at:

Tcelltech
Email:
linxiaojuan@tcelltech.com

Gangxiong Huang, MD

Co-founder, CEO

Dr. Huang’s research has focused on tumor metastasis and T-cell immunotherapy. He completed his postdoctoral training and subsequently served as a researcher at The University of Texas MD Anderson Cancer Center. He also served as a pathologist and Minjiang Scholar Professor at Fujian Medical University previously.

Lieping Chen, MD, PhD​

Co-founder, Scientific advisor

Dr. Chen is a pioneer in cancer immunotherapy. His research focuses on fundamental T-cell biology and the translation of scientific discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. He discovered PD-L1 and established its role in tumor immune evasion, laying the foundation for anti-PD-1/PD-L1 therapies that have transformed cancer treatment worldwide. Among his other numerous discoveries, B7-H3 has emerged as a promising universal therapeutic target for solid tumors. 

Dr. Chen is United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine at Yale University. He held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. Dr. Chen is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.